Cellular and humoral immune responses to pandemic influenza vaccine in healthy and in highly active antiretroviral therapy-treated HIV patients

AIDS Research and Human Retroviruses

Volumn 28, Issue 12, 2012, Pages 1606-1616

  Agrati, Chiara ^a   Gioia, Cristiana ^a   Castilletti, Concetta ^a   Lapa, Daniele ^a   Berno, Giulia ^a   Puro, Vincenzo ^a   Carletti, Fabrizio ^a   Cimini, Eleonora ^a   Nisii, Carla ^a   Castellino, Flora ^b   Martini, Federico ^a   Capobianchi, Maria R ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

1889 RUSSIAN INFLUENZA; ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HEALTH CARE PERSONNEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMORAL IMMUNITY; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; PANDEMIC INFLUENZA; PRIORITY JOURNAL; SEASONAL INFLUENZA; SINGLE DRUG DOSE; VIRUS STRAIN;

ADULT; AGED; ANTIBODIES, VIRAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CYTOKINES; FEMALE; HIV INFECTIONS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED;

EID: 84865423494     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0371     Document Type: Article

References (57)

1. Rambaut A, Pybus OG, Nelson MI, et al.: The genomic and epidemiological dynamics of human influenza A virus. Nature 2008;453(7195):615-619.
2. Taubenberger JK, Reid AH, Lourens RM, et al.: Characterization of the 1918 influenza virus polymerase genes. Nature 2005;437(7060):889-893.
3. Shinde V, Bridges CB, Uyeki TM, et al.: Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009. N Engl J Med 2009;360(25):2616-2625.
4. Update: novel influenza A (H1N1) virus infections-worldwide, May 6, 2009. MMWR Morb Mortal Wkly Rep 2009; 58(17):453-458.
5. Chowell G, Bertozzi SM, Colchero MA, et al.: Severe respiratory disease concurrent with the circulation of H1N1 influenza. N Engl J Med 2009;361(7):674-679.
6. Girard MP, Tam JS, Assossou OM, and Kieny MP: The 2009 A (H1N1) influenza virus pandemic: A review. Vaccine 2010;28(31):4895-4902.
7. Human infection with new influenza A (H1N1) virus: Clinical observations from Mexico and other affected countries, May 2009. Wkly Epidemiol Rec 2009;84(21):185-189.
8. Klein MB, Lu Y, DelBalso L, Cote S, and Boivin G: Influenza virus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination. Clin Infect Dis 2007;45(2):234-240.
9. Lin JC and Nichol KL: Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med 2001;161(3):441-446.
10. Safrin S, Rush JD, and Mills J: Influenza in patients with human immunodeficiency virus infection. Chest 1990;98(1):33-37.
11. Riera M, Payeras A, Marcos MA, et al.: Clinical presentation and prognosis of the 2009 H1N1 influenza A infection in HIV-1-infected patients: A Spanish multicenter study. AIDS 2010;24(16):2461-2467.
12. Sheth AN, Patel P, and Peters PJ: Influenza and HIV: Lessons from the 2009 H1N1 influenza pandemic. Curr HIV/AIDS Rep 2011;8(3):181-191.
13. Ormsby CE, Rosa-Zamboni D, Vazquez-Perez J, et al.: Severe 2009 pandemic influenza A (H1N1) infection and increased mortality in patients with late and advanced HIV disease. AIDS 2011;25(4):435-439.
14. Updated interim recommendations: HIV-infected adults and adolescents-considerations for clinicians regarding 2009 H1N1 influenza: (http://www cdc gov/h1n1flu/guidance- HIV htm) 2011.
15. Zanetti AR, Amendola A, Besana S, Boschini A, and Tanzi E: Safety and immunogenicity of influenza vaccination in individuals infected with HIV. Vaccine 2002;20(Suppl 5):B29-B32.
16. Tasker SA, Treanor JJ, Paxton WB, and Wallace MR: Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999;131(6):430-433.
17. Prevention and Control of Influenza with Vaccines. MMWR Morb Mortal Wkly Rep 2010;59.
18. Bickel M, Wieters I, Khaykin P, et al.: Low rate of serocon-version after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS 2010;24(9):F31-F35.
19. Kajaste-Rudnitski A, Galli L, Nozza S, et al.: Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. AIDS 2011;25(2):177-183.
20. Tebas P, Frank I, Lewis M, et al.: Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS 2010;24(14):2187-2192.
21. Crum-Cianflone NF, Eberly LE, Duplessis C, et al.: Im-munogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: A prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis 2011;52(1):138-146.
22. Manuel O, Pascual M, Hoschler K, et al.: Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis 2011;52(2):248-256.
23. Orlando G, Pariani E, Mazza F, et al.: Pandemic influenza vaccine in adult HIV1-infected patients. AIDS 2010;24(13):2142-2143.
24. McMichael AJ, Gotch FM, Noble GR, and Beare PA: Cyto-toxic T-cell immunity to influenza. N Engl J Med 1983;309(1):13-17.
25. Webby RJ, Andreansky S, Stambas J, et al.: Protection and compensation in the influenza virus-specific CD8+ T cell response. Proc Natl Acad Sci USA 2003;100(12):7235-7240.
26. McElhaney JE, Xie D, Hager WD, et al.: T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006;176(10):6333- 6339.
27. Bender BS, Croghan T, Zhang L, and Small PA Jr: Transgenic mice lacking class I major histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge. J Exp Med 1992;175(4):1143-1145.
28. Cusick MF, Wang S, and Eckels DD: In vitro responses to avian influenza H5 by human CD4 T cells. J Immunol 2009;183(10):6432-6441.
29. Forrest BD, Pride MW, Dunning AJ, et al.: Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008;15(7):1042-1053.
30. Agrati C, Gioia C, Lalle E, et al.: Association of profoundly impaired immune competence in H1N1v-infected patients with a severe or fatal clinical course. J Infect Dis 2010;202(5):681-689.
31. Rimmelzwaan GF, Kreijtz JH, Bodewes R, Fouchier RA, and Osterhaus AD: Influenza virus CTL epitopes, remarkably conserved and remarkably variable. Vaccine 2009;27(45):6363-6365.
32. Gioia C, Castilletti C, Tempestilli M, et al.: Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. Emerg Infect Dis 2008;14(1):121-128.
33. Berthoud TK, Hamill M, Lillie PJ, et al.: Potent CD8 + T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+ M1. Clin Infect Dis 2011; 52(1):1-7.
34. Laboratory-Based Surveillance o£ Influenza Virus Infections: (http://whqlibdoc who int/publications/1982/a86910-partA pdf), 1982.
35. Arguedas A, Soley C, and Lindert K: Responses to 2009 H1N1 vaccine in children 3 to 17 years of age. N Engl J Med 2010;362(4):370-372.
36. EMEA: http://www emea europa eu/docs/en-GB/document-library/Scientific- guideline/2009/09/WC500003869 pdf 2011.
37. Schanen BC, De Groot AS, Moise L, et al.: Coupling sensitive in vitro and in silico techniques to assess cross-reactive CD4(+) T cells against the swine-origin H1N1 influenza virus. Vaccine 2011;29(17):3299-3309.
38. Anker WJ, Bakker AK, and Masurel N: Cross-protection in mice after immunization with H2N2, H3N2, and Heq2Neq2 influenza virus strains. Infect Immun 1978;21(1):96-101.
39. Flynn KJ, Belz GT, Altman JD, et al.: Virus-specific CD8+ T cells in primary and secondary influenza pneumonia. Immunity 1998;8(6):683-691.
40. Hillaire ML, van Trierum SE, Kreijtz JH, et al.: Cross-protective immunity to influenza pH1N1 2009 viruses induced by seasonal A(H3N2) virus is mediated by virus-specific T cells. J Gen Virol 2011;92:2339-2349.
41. Lee LY, Ha do LA, Simmons C, et al.: Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 2008;118(10):3478-3490.
42. Stanekova Z and Vareckova E: Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. Virol J 2010;7:351.
43. Liang S, Mozdzanowska K, Palladino G, and Gerhard W: Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J Immunol 1994; 152(4):1653-1661.
44. Nguyen HH, Moldoveanu Z, Novak MJ, et al.: Hetero-subtypic immunity to lethal influenza A virus infection is associated with virus-specific CD8(+) cytotoxic T lymphocyte responses induced in mucosa-associated tissues. Virology 1999;254(1):50-60.
45. Rimmelzwaan GF and Osterhaus AD: Cytotoxic T lymphocyte memory: Role in cross-protective immunity against influenza? Vaccine 1995;13(8):703-705.
46. Christensen JP, Doherty PC, Branum KC, and Riberdy JM: Profound protection against respiratory challenge with a lethal H7N7 influenza A virus by increasing the magnitude of CD8 (+) T-cell memory. J Virol 2000;74(24):11690- 11696.
47. O'Neill E, Krauss SL, Riberdy JM, Webster RG, and Woodland DL: Heterologous protection against lethal A/Hon-gKong/156/97 (H5N1) influenza virus infection in C57BL/6 mice. J Gen Virol 2000;81(Pt 11):2689-2696.
48. Seo SH and Webster RG: Cross-reactive, cell-mediated immunity and protection of chickens from lethal H5N1 influenza virus infection in Hong Kong poultry markets. J Virol 2001;75(6):2516-2525.
49. Weinfurter JT, Brunner K, Capuano SV, III, et al.: Cross-reactive T cells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primates. PLoS Pathog 2011;7(11):e1002381.
50. Epstein SL: Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: An experiment of nature. J Infect Dis 2006;193(1):49-53.
51. Kreijtz JH, de MG, van Baalen CA, et al.: Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J Virol 2008;82(11):5161-5166.
52. Subbramanian RA, Basha S, Shata MT, Brady RC, and Bernstein DI: Pandemic and seasonal H1N1 influenza hemagglutinin-specific T cell responses elicited by seasonal influenza vaccination. Vaccine 2010;28(52):8258-8267.
53. Duvvuri VR, Moghadas SM, Guo H, et al.: Highly conserved cross-reactive CD4+ T-cell HA-epitopes of seasonal and the 2009 pandemic influenza viruses. Influenza Other Respir Viruses 2010;4(5):249-258.
54. Uchida T: Development of a cytotoxic T-lymphocyte-based, broadly protective influenza vaccine. Microbiol Immunol 2011;55(1):19-27.
55. Sun K, Ye J, Perez DR, and Metzger DW: Seasonal FluMist vaccination induces cross-reactive T cell immunity against H1N1 (2009) influenza and secondary bacterial infections. J Immunol 2011;186(2):987-993.
56. LaSalle JM and Hafler DA: T cell anergy. FASEB J 1994; 8(9):601-608.
57. Keynan Y, Card CM, Ball BT, et al.: Cellular immune responses to recurring influenza strains have limited boosting ability and limited cross-reactivity to other strains. Clin Microbiol Infect 2010;16(8):1179-1186.